CHD1 Deletion: Implications to Outcome and Treatment in Prostate Cancer

Project Information

CDELP

Grant agreement ID: 625792

Closed project

Start date 4 April 2014

End date 3 April 2016

Funded under

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Total cost € 231 283,20

EU contribution € 231 283,20

Coordinated by

INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG
United Kingdom

Objective

Prostate cancer can be stratified as ETS gene rearranged (ETSR) and
non-rearranged (ETSNR), with the latter comprising a heterogeneous
group of 50-60% of all cancers. This project will characterize a subgroup
of ETSNR cancers that have a CHD1 deletion (CHD1del). Recent
sequencing studies have elucidated CHD1- cancers as ETSNR, and
commonly PTEN and p53 wildtype and SPOP mutated, comprising up to
26% of all prostate cancers (1). ETSR cancers largely have hormone
driven oncogenes that may have prognostic and predictive utility (2, 3).
Less is known about ETSNRCHD1del cancers. Their lack of ETS fusions
raises concern that these may not be generated through androgen
receptor (AR) transcription and are not AR driven. ETSNRCHD1del cancers
have a huge excess of somatic intrachromosomal rearrangements (up to
800) compared to ETSR cancers presumably due to a DNA repair defect
(1). This is supported by CHD1’s association with the SSRP1, part of the
FACT complex, that is implicated in transcriptional regulation and DNA
repair (4-9). We hypothesize that CHD1 deleted tumors are less
sensitive to endocrine and taxane therapy, have a worse prognosis
and need alternative treatment strategies.

Fields of science

• medical and health sciences › clinical medicine › oncology › prostate cancer
• natural sciences › biological sciences › genetics › DNA

Programme(s)

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Topic(s)

• FP7-PEOPLE-2013-IIF - Marie Curie Action: "International Incoming Fellowships"

Call for proposal

FP7-PEOPLE-2013-IIF
See other projects for this call

Funding Scheme

MC-IIF - International Incoming Fellowships (IIF)

Coordinator

INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG

Administrative Contact

Lydia Turner (Ms.)

• EU contribution: € 231 283,20
• Address: OLD BROMPTON ROAD 123 ; SW7 3RP London ; United Kingdom
• Region: London › Inner London — West › Kensington & Chelsea and Hammersmith & Fulham
• Activity type: Higher or Secondary Education Establishments
• Total cost: No data